Greater Patient-Physician Communication Increases Surveillance Adherence

Share this content:

(ChemotherapyAdvisor) – Patient-clinician information engagement after curative treatment for colorectal cancer resulted in 2.8 times the number of patients reporting adherence to recommended surveillance at 1 year, a longitudinal study reported in The Oncologist online August 2.

While several demographic and disease-related factors are known to be associated with adherence, “thus far, patient-centered communication has not been studied as a determinant for undergoing cancer surveillance,” Andy S.L. Tan, MBBS, MPH, MBA, Center of Excellence in Cancer Communication Research, Annenberg School for Communication, University of Pennsylvania, Philadelphia, PA, and colleagues noted.

In this study, 305 patients diagnosed with colorectal cancer in 2005 who were eligible for surveillance completed surveys at baseline and 1 year. Self-reported adherence to physical examination, carcinoembryonic antigen testing, and colonoscopy according to recommended guidelines comprised the primary outcome measure.

“Greater patient engagement with clinicians about cancer-related information was found to improve patients' subsequent adherence to recommended surveillance,” Dr. Tan reported. A higher education level and having received systemic therapy were also significant predictors of adhering to recommended surveillance.

The investigators concluded that these results support encouragement of greater patient-physician communication among patients with colorectal cancer.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs